Chitosan Iron(III) Reduces Phosphorus Levels in Alloxan Diabetes-Induced Rats with Signs of Renal Failure Development

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 6, 2010, Pages 467-471

  Schöninger, Lisiane M R ^a   Dall'Oglio, Rafaela C ^a   Sandri, Silvana ^a   Rodrigues, Clóvis A ^a   Bürger, Cristiani ^a  

^a UNIVERSIDADE DO VALE DO ITAJAÍ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOXAN; CHITOSAN; IRON; CHLORIDE; CROSS LINKING REAGENT; FERRIC CHLORIDE; FERRIC ION; PHOSPHATE; PHOSPHORUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASOPHIL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFICACY; EOSINOPHIL; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBIN BLOOD LEVEL; IRON BLOOD LEVEL; KIDNEY FAILURE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MONOCYTE; NEUTROPHIL COUNT; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RAT; THROMBOCYTE COUNT; TREATMENT RESPONSE; ANIMAL; BLOOD; CHEMISTRY; COMPLICATION; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; INTESTINE ABSORPTION; METABOLISM; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY; SEX DIFFERENCE; WISTAR RAT;

ALLOXAN; ANIMALS; CHITOSAN; CHLORIDES; CROSS-LINKING REAGENTS; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; FERRIC COMPOUNDS; INTESTINAL ABSORPTION; IRON; KIDNEY FAILURE; MALE; PHOSPHATES; PHOSPHORUS; RATS; RATS, WISTAR; SEX FACTORS; RENAL INSUFFICIENCY;

ANIMALIA; RATTUS;

EID: 77952245508     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00527.x     Document Type: Article

References (15)

1. Baxter J, Shimizu F, Takiguchi Y, Wada M. Effect of iron(III) chitosan intake on the reduction of serum phosphorus in rats. J Pharm Pharmacol 2000 52 : 863 874.
2. Altmann P, Barnett ME, Finn WF. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 2007 71 : 252 259.
3. Bellasi A, Kooienga L, Block GA. Phosphate binders: new products and challenges. Hemodial Int 2006 10 : 225 234.
4. Bushinsky DA. Phosphate binders: hold the calcium? Clin J Am Soc Nephro 2006 1 : 695 696.
5. El-Abbadi M, Giachelli CM. Mechanisms of vascular calcification. Adv Chronic Kidney D 2007 14 : 54 66.
6. Qunibi WY. The CARE study and cardiovascular calcification. Manag Care 2006 15 : 1 5.
7. Hergesell O, Ritz E. Phosphate binders on iron basis: a new perspective? Kidney Inter 1999 56 (Suppl 1 S42 5.
8. Hsu CH, Patel SR, Young EW. New phosphate binding agents: ferric compounds. J Am Soc Nephrol 1999 10 : 1274 1280.
9. Zhu L, Ma J, Jia N, Zhao Y, Shen H. Chitosan-coated magnetic nanoparticles as carriers of 5-fluoruracil: preparation, characterization and cytotoxicity studies. Colloids and Surf, B 2009 68 : 1 6.
10. Bürger C, Valcarenghi D, Sandri S, Rodrigues CA. Cross-linking chitosan-Fe(III), an oral phosphate binder studies in vitro and in vivo. Int J Pharm 2001 223 : 29 33.
11. Menezes HS. Ética e pesquisa em animais. Rev AMRIGS 2002 46 : 105 108.
12. Fagundes T, Bernardi EL, Rodrigues CA. Phosphate adsorption on chitosan-Fe(III)-cross-linking: batch and column studies. J Liq Chrom Rel Technol 2001 24 : 1189 1198.
13. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001 50 : 536 546.
14. Schwarz KB, Zimmerman DC, Alpers DH, Avioli LV. Gender differences in antacid-induced phosphate deprivation in rats. Gastroenterology 1985 89 : 313 320.
15. Smith EH, Martel AE. Critical Stability Constant, Vol 2. Plenum Press